目的 探討益腎康膠囊與阿魏酸哌嗪聯(lián)合治療慢性腎小球腎炎的臨床療效。方法 選擇2019年12月—2021年12月在華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬梨園醫(yī)院診療的98例腎炎患者，隨機(jī)分為對照組和治療組，每組各49例。對照組口服阿魏酸哌嗪片，100～200 mg/次，1次/d。在對照組基礎(chǔ)上，治療組口服益腎康膠囊，2粒/次，1次/d。兩組患者治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀緩解時間，尿蛋白指標(biāo)24 h-尿蛋白定量（24 h-Upro）、尿微量白蛋白（mALB）和β₂-微球蛋白（β₂-MG），血清白細(xì)胞介素-1（IL-1）、白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）和γ干擾素（IFN-γ）水平，及不良反應(yīng)情況。結(jié)果 治療后，治療組臨床有效率為97.96%，顯著高于對照組的79.59%（P＜0.05）。治療后，治療組癥狀緩解時間均早于對照組（P＜0.05）。治療后，兩組24 h-Upro、尿mALB、β₂-MG、IL-6、IL-1、TNF-α、IFN-γ水平均降低，治療組水平低于對照組（P＜0.05）。治療期間，治療組不良反應(yīng)率為8.16%，明顯低于對照組的18.36%（P＜0.05）。結(jié)論 阿魏酸哌嗪聯(lián)合益腎康膠囊治療慢性腎小球腎炎能提高有效治療率，并改善尿蛋白指標(biāo)，降低炎性反應(yīng)的水平。

Objective To investigate the clinical effect of Yishenkang Capsules combined with piperazine ferulate in treatment of chronic glomerulonephritis. Methods Patients (98 cases) with chronic glomerulonephritis in Liyuan Hospital to Tongji Medical College of Huazhong University of Science and Technology from December 2019 to December 2021 were randomly divided into control and treatment group, and each had 49 cases. Patients in the control group were po administered with Piperazine Ferulate Tablets, 100-200 mg/time, once daily. Patients in the treatment group were po administered with Yishenkang Capsules on the basis of the control group, 2 grains/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, the urine protein indexes 24 h-Upro, mALB and β₂-MG, the levels of IL-6, IL-1, TNF-α and IFN-γ, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 97.96%, which was significantly higher than that of the control group (79.59%, P < 0.05). After treatment, the time of symptom relief in the treatment group was earlier than that in the control group (P < 0.05). After treatment, the symptom relief time in treatment group was earlier than that in control group (P < 0.05). After treatment, the levels of 24 h-Upro, urinary mALB, β₂-MG, IL-6, IL-1, TNF-α and IFN-γ in both groups were decreased, and the levels in treatment group were lower than those in control group (P < 0.05). During the treatment, the rate of adverse reactions in the treatment group was 8.16%, which was significantly lower than 18.36% in the control group (P < 0.05). During the treatment, the adverse reaction rate in the treatment group was 8.16%, which was significantly lower than that in the control group (18.36%) (P < 0.05). Conclusion Yishenkang Capsules combined with piperazine ferulate in treatment of chronic glomerulonephritis can improve the effective treatment rate, improve the index of urinary protein and reduce the level of inflammatory reaction.

R983